Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04466761
Other study ID # 1516913
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 23, 2022
Est. completion date December 2024

Study information

Verified date September 2023
Source University of California, Davis
Contact Emanual Maverakis, MD
Phone 916-551-2635
Email emaverakis@ucdavis.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will conduct a parallel-group, placebo-controlled, randomized, double-blind ascending dose Phase I study of dietary supplementation in healthy individuals to evaluate safety and to determine the pharmacologically effective dose (ED).


Recruitment information / eligibility

Status Recruiting
Enrollment 65
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Patients must be 18-45 years of age - Patients who are in general good health - Body Mass Index (BMI) range of 18.5-25 - All individuals must have the ability to provide inform consent Exclusion Criteria: - Women who are pregnant, actively nursing, or pregnant within the last year - Women who are peri-menopausal or post-menopausal - Women with irregular menstrual cycles (more frequently than every 21 days or lasts longer than 8 days (missed, early, or late periods are also considered signs of an irregular cycle). - Women on hormonal contraception, including birth control, hormonal intrauterine device, or contraceptive implant - Past medical history of an autoimmune condition or malignancy, excluding non-melanoma skin cancer - Individuals with first degree relative with history of an autoimmune condition - Individuals with cardiovascular, pulmonary, reproductive, endocrine, metabolic, neurologic, gastrointestinal, hematologic, or infectious diseases of any kind - Individuals with diagnosis of galactosemia or congenital disorders of glycosylation - Individuals with phenylketonuria - Individuals currently taking prescription medications, or have taken prescription medications within the last 3 months - Individuals currently taking over the counter medications - Individuals currently taking or have taken supplements including herbal, protein or vitamin supplements in the last 3 months (e.g. whey protein, St. John's Wort, green tea supplements, biotin, creatine supplements), excluding multivitamins or essential vitamins - Individuals with prior history of severe food or drug allergic reactions - Individuals with a diagnosis of type I or II diabetes mellitus - Individuals with allergic reaction or adverse reaction to shellfish, N-acetyl glucosamine, galactose, or Spirulina/chlorella/algae supplements - Individuals with social history of current use of tobacco, alcohol or other drugs - Individuals with dietary restrictions (vegetarians are permitted to participate in the study) or to whom any of the following dietary habits or characteristics apply (the following exclusion criteria are placed to minimize variability in diet in our study population): - Actively dieting or trying to lose weight - Vegan diet - Consume equal to or greater than 2 cups of tea a day - Consume equal to or greater than 4 cups of coffee a day - Consume equal to or greater than 3 cups of fruit juice a day - Practice intensive exercise patterns (marathon training, workouts >4 hours a day) - Consume soda or energy drinks of any amount - On a carbohydrate-restricted or "Paleo" diet - Calorie-restricted diet (less than 20%-25% of maintenance calories)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Monosaccharide Powder
Monosaccharide powder dissolved in water.
Other:
Placebo Comparator
Placebo (cellulose powder).

Locations

Country Name City State
United States University of California, Davis Medical Center Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Characterize Immunoglobulin fragment crystallization modifications Use mass spectrometry and RNA sequencing from subject blood samples to characterize site specific glycosylation on Immunoglobulin A, Immunoglobulin M, and Immunoglobulin G. 4 Weeks
Primary Identify the maximum effective dose Identify maximum effective dose of dietary supplement in grams/day. 16 Weeks
Secondary Assess for potential adverse events Monitor symptoms, severity, and duration of adverse events. 2 Months after first dose
Secondary Quantification of enzymatic modifications measured in grams by spectrometry The investigators will measure enzymatic changes on glycoproteins in the immune system by spectrometry, i.e., these changes will be measured in grams. Spectometry will allow the investigators to quantify these changes in small detail, and therefore give a better idea of how supplementation can change enzymatic process that then affect the structure, and mass, of glycoproteins. 6 Months
Secondary Flow cytometry to determine the effect of dietary supplementation on the immune system Perform flow cytometry on subject blood samples to determine the effect of dietary supplement on immune system. For example, the investigators will note changes to immune cell pro-inflammatory and anti-inflammatory cytokine clusters as translated proteins (measured as height and area of cytokine intensity). 6 Months
Secondary Transcriptome analysis to determine the effect of dietary supplementation on the immune system Perform transcriptome analysis on subject blood samples to determine the effect of dietary supplement on immune system. For example, the investigators will note changes to immune cell pro-inflammatory and anti-inflammatory cytokine clusters as RNA (measure on a logarithmic scale per number of reads) to determine the effects of supplementation on both gene transcription and translation. 6 Months
See also
  Status Clinical Trial Phase
Completed NCT06044896 - Physiology of Body Lateralization on Regional Lung Ventilation Study N/A
Completed NCT02101801 - Urine Drug Levels Related to Source of Water for Irrigation for Vegetable Crops Among Healthy Israeli Volunteers N/A
Recruiting NCT06101641 - Effect of Shellac Nail Polish Application on Pulse Oximetry Measurements in Healthy Individuals N/A
Completed NCT03065283 - Effects of Diaphragm-releasing Techniques on the Lumbar Spine and Diaphragmatic Function in Healthy Women N/A
Recruiting NCT01721811 - Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism N/A
Completed NCT01211717 - The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients N/A
Completed NCT01568541 - Fluoride Intake From Toothbrushig With Children's or Regular Toothpastes N/A
Completed NCT04941196 - Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition Phase 1
Completed NCT05541094 - Study of Vitamin D Fortification of Milk and Oil
Completed NCT05597657 - Normal Variation of T1 Values With Cardiac Magnetic Resonance in Healthy Individuals N/A
Completed NCT03728868 - Tolerability and Risk of Adverse Events With a Probiotic Supplement N/A
Recruiting NCT04513782 - The Contributions of Age Related Changes in the Sound Localization Pathway to Central Hearing Loss
Completed NCT05637060 - Bioequivalence Study of Rosuvastatin Tablet N/A
Not yet recruiting NCT05110885 - Public AttitudesTowards SMA and DMD Awareness, Newborn and Carrier Screening and Physiotherapy Practices
Completed NCT01134978 - Neural Mechanisms of the Contextual Interference Effect: A fNIRs and EEG Study Phase 1
Completed NCT06137534 - Upper Extremity Pattern Exercises and Respiratory Functions N/A
Completed NCT04873570 - Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects Phase 1
Enrolling by invitation NCT01872091 - Analysis of Neuromuscular, Circulatory and Biomechanical Responses After Cryotherapy N/A
Completed NCT01872117 - Assessment of Temperature by Infrared Thermography and Blood Conduction Velocity by Doppler After Applying Shortwave Diathermy and Microwave - Correlations With Cardiovascular and Hemodynamic Parameters N/A
Completed NCT02409836 - A Study to Assess the Ingestion of Dentifrice by Children N/A